EMMANUEL(BACHY((LYON)
CHALLENGES(IN(FL(–(POD24
Between! 15! to! 25%! of! patients! with! FL! will! relapse! between! the! first! 2! years! following!
immunochemotherapy!(IC).!It!has!been!demonstrated!that!subsequent!overall!survival!(OS)!
following!progression!of!disease!(POD)!during!the!first!2!years!is!much!poorer!than!for!the!
others.! This! subset! of! patients! has! been! designed! by! the! usual! term! “POD24>positive”!
patients.! Here! we! discussed! the! different! pre>! and! post>treatment! prognostic! parameters!
used!in!FL!(IPI,!FLIPI,!FLIPI2,!PRIMA>PI,!FLEX,!PET>CT!at!end!of!induction,!CR30,!EFS12,!POD24!
etc…)!with!a!particular!emphasis!on!POD24.!We!show!how!POD24!is!a!very!good!correlate!
for! subsequent! OS.! However,! using! the! example! of! the! PRIMA! trial,! we! also! demonstrate!
that! POD24! cannot! be! used! as! a! surrogate! marker! for! OS! (ie,! a! treatment! that! decreases!
POD24!proportion!does!not!necessarily!prolong!OS),!a!more!and!more!common!belief!in!the!
hematological!field.!Finally,!comparing!POD24!rates!for!patients!receiving!different!first!line!
regimen! should! be! undertaken! with! extreme! caution.! Finally,! we! will! discuss! what!
therapeutic! options! can! be! adopted! for! those! early>relapsing! patients,! and! especially! the!
role!of!autologous!stem!cell!transplant.!
!!!
!
!
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES